Personalis (PSNL) Stock Price, News & Analysis

Company Overview

Personalis, Inc. (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development. These include targeted oncology panels, whole exome sequencing (WES) and RNA sequencing (RNA‐Seq) services, as well as specialty assays for infectious disease research. Personalis combines its laboratory operations—based in Menlo Park, California—with cloud‐based analytics to deliver scalable, quality‐controlled data across research and clinical workflows.

Founded in 2011 and headquartered in Menlo Park, California, Personalis completed its initial public offering in July 2014. Since then, the Company has expanded its geographic reach, serving customers across North America, Europe and Asia. Its laboratories maintain CLIA certification and CAP accreditation, enabling support for both research‐use and regulated clinical applications. Personalis also collaborates with pharmaceutical and biotechnology partners on co‐development programs to accelerate the translation of genomic data into novel therapies.

Personalis is led by President and Chief Executive Officer John West, who brings more than two decades of leadership in biotechnology and personalized medicine. Under his direction, the Company has grown its scientific and operational teams, investing in automation, data analytics and assay innovation. With a focus on comprehensive genomic insights, Personalis aims to advance the understanding of cancer biology and improve patient outcomes through precision diagnostics.

Key Stats

• Today's Range: $7.70 to $8.58
• 50-Day Range: $5.04 to $8.31
• 52-Week Range: $3.84 to $11.50
• Volume: 2.88 million shs
• Average Volume: 1.70 million shs
• Market Capitalization: $856.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Personalis Stock Analysis - MarketRank™

Personalis scored higher than 45% of companies evaluated by MarketBeat, and ranked 590th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Personalis has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Personalis has a consensus price target of $11.00, representing about 32.2% upside from its current price of $8.32.

Amount of Analyst Coverage

Personalis has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Personalis are expected to grow in the coming year, from ($1.06) to ($0.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Personalis is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Personalis is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Personalis has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.06% of the float of Personalis has been sold short.

Short Interest Ratio / Days to Cover

Personalis has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Personalis has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Personalis does not currently pay a dividend.

Dividend Growth

Personalis does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.33

News Sentiment

Personalis has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Personalis this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added Personalis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Personalis insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.20% of the stock of Personalis is held by insiders.

Percentage Held by Institutions

61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/21/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PSNL
• CIK: 1527753
• Web: www.personalis.com
• Phone: (650) 752-1300
• Fax: N/A
• Employees: 400
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Personalis: $11.00
• High Price Target: $13.00
• Low Price Target: $9.00
• Potential Upside/Downside: +32.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.27 million
• Net Margins: -148.11%
• Pretax Margin: -148.06%
• Return on Equity: -43.52%
• Return on Assets: -32.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.61
• Quick Ratio: 6.44

Sales & Book Value

• Annual Sales: $69.65 million
• Price / Sales: 12.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.43 per share
• Price / Book: 3.41

Miscellaneous

• Outstanding Shares: 104,720,000
• Free Float: 100,323,000
• Market Cap: $868.65 million
• Optionable: Optionable
• Beta: 1.96